-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

Barchart·09/14/2026 17:00:00
Listen to the news

- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis
-
Ascendis to initiate multiple programs in metabolic and cardiovascular diseases, including obesity

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.